Breast Cancer

The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial. The findings were presented at the American Society of Clinical Oncology 2021 virtual annual meeting by lead investigator Giuseppe Curigliano, MD, PhD, Associate Professor, Medical Oncology, University of Milano, Italy. Read Article ›

The recent approval of several new HER2-targeted therapies has led to significant advances in the treatment of patients with HER2-positive metastatic breast cancer. During the 2021 Hematology/Oncology Pharmacy Association Annual Conference, Kelly Gaertner, PharmD, BCOP, BCPS, Clinical Pharmacy Specialist, Hematology/Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, discussed data from recent clinical trials evaluating these agents, including their potential to improve outcomes in patients with brain metastases. Read Article ›

Breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, appears to be an effective alternative to surgery for women aged >60 years with low-risk, early-stage breast cancer, according to interim results from the ICE3 trial. Interim results from this trial were presented by lead investigator Richard E. Fine, MD, FACS, Breast Surgeon, West Cancer Center & Research Institute, Germantown, TN, during the American Society of Breast Surgeons 22nd Annual Meeting. Read Article ›

Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction surgery among non-Hispanic black women and women with lower income and education levels, according to results of a study presented during the American Society of Breast Surgeons 22nd Annual Meeting. At times, these increases achieved parity with non-Hispanic white women. Read Article ›

Physicians often fail to perceive radiation-associated symptoms and the severity of those symptoms, according to the results of a large observational study that compared the reports of patients with breast cancer with physicians’ assessments of 4 common radiation-associated symptoms. Physicians were also more likely to underrecognize the severity of these symptoms in younger women and black women with breast cancer. Read Article ›

Sacituzumab govitecan (Trodelvy) led to increased response rates and improved progression-free survival (PFS) compared with chemotherapy in heavily pretreated patients with metastatic triple-negative breast cancer (TNBC) and stable brain metastases, according to a subgroup analysis of the phase 3 ASCENT clinical trial. The drug did not lead to improved overall survival (OS) in patients with stable brain metastases. These results were presented at the virtual 2020 San Antonio Breast Cancer Symposium (SABCS). Read Article ›

Pembrolizumab (Keytruda) plus chemotherapy improved progression-free survival (PFS) compared with chemotherapy alone as first-line treatment of metastatic triple-negative breast cancer (TNBC), according to the results of KEYNOTE-355. Improvement in PFS with the addition of pembrolizumab to chemotherapy was more robust in patients with TNBC and PD-L1 expression. These results were presented at the virtual 2020 San Antonio Breast Cancer Symposium (SABCS) and add to a growing body of evidence supporting the first-line use of pembrolizumab plus chemotherapy combinations for TNBC. Read Article ›

The addition of the cyclin-dependent kinase (CDK)4/6 inhibitor abemaciclib (Verzenio) to standard endocrine therapy reduced the risk for invasive disease recurrence or death compared with endocrine therapy alone by almost 30% in patients with high-risk, hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative, early-stage breast cancer. These results come from the primary analysis of the phase 3 monarchE clinical trial that was presented at the virtual 2020 San Antonio Breast Cancer Symposium. Read Article ›

Results of the SWOG S1007 RxPONDER clinical trial suggest that some postmenopausal women with early-stage hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative breast cancer, and 1 to 3 positive axillary lymph nodes may be able to avoid adjuvant chemotherapy. By contrast, premenopausal women can derive benefit from adjuvant chemotherapy, based on findings of a prespecified interim analysis of the phase 3 RxPONDER clinical trial; the findings were presented at the virtual 2020 San Antonio Breast Cancer Symposium. Read Article ›


Want more Breast Cancer-related news?

Sign up for the OPM weekly e-Newsletter!

Enter your contact information below to recieve weekly oncology news & updates.

Page 1 of 12

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: